



## **Endo and Jubilant Expand Oncology Discovery Partnership on Successful Delivery of Early Milestone**

**Bangalore, India, January 27, 2010** -- Jubilant Biosys Ltd., a subsidiary of Jubilant Organosys Ltd., and Endo Pharmaceuticals (Nasdaq: ENDP), of Chadds Ford, Pa., U.S.A., announced today that they have expanded their drug discovery partnership in oncology, following the successful delivery of an early stage milestone.

The year-old partnership focuses on Jubilant delivering preclinical candidates in the therapeutic area of oncology. Endo owns the late-stage development and commercialization rights for molecules discovered in the partnership. Jubilant derives research funding and success-based development and commercialization milestones.

Commenting on this development, **Sri Mosur, CEO & President, Global Drug Discovery & Development** said: "We are pleased that we could deliver early success to the discovery portfolio efforts at Endo Pharmaceuticals and this expansion is a testimony to Jubilant's focus in building world class oncology capabilities, among other therapeutic areas. This collaboration further reinforces the concept of globally leveraged R&D that creates a platform for scientists from Endo and Jubilant to collaborate in finding affordable remedies for cancer patients worldwide."

"We have been impressed by the quality of the science and the progress made to date by the Jubilant team on our ongoing oncology discovery program, said **Dr. Ivan Gergel, M.D, Executive Vice President of R&D at Endo Pharmaceuticals**. "Expanding our relationship in this important therapeutic area is consistent with our strategy of building Endo's pipeline using a virtual discovery approach, in conjunction with our in-licensing efforts."

### **About Jubilant Biosys**

Jubilant Biosys Ltd. (JBL) ([www.jubilantbiosys.com](http://www.jubilantbiosys.com)), a subsidiary of Jubilant Organosys Ltd., provides integrated drug discovery and development solutions to the global pharmaceutical industry. Jubilant Biosys has an integrated state of the art facility in Bangalore. The Center houses over 450 scientists specializing in multiple



disciplines to include Discovery biology, medicinal chemistry, structural biology, pharmacology, toxicology, pharma chem, molecular modeling, crystallography and information technology supporting discovery efforts.

### **About Jubilant Organosys Limited**

Jubilant Organosys Ltd., headquartered at Noida, an integrated pharmaceutical industry player, is India's largest Custom Research and Manufacturing Services company (CRAMS) and a leading Drug Discovery and Development Solution Provider. The company has a presence across the pharmaceutical value chain for providing products and services such as proprietary products, exclusive synthesis, active pharmaceutical ingredients, contract manufacturing of sterile injectables & non-steriles products, radiopharmaceuticals, generic dosage forms, drug discovery services, medicinal chemistry services, clinical research services, and Health Care. The Company also manufactures Industrial and Performance products.

[www.jubl.com](http://www.jubl.com)

### ***For Business Queries***

Kailash Swarna

Sr. VP and COO,

Jubilant Drug Discovery and Development

[kailash\\_swarna@jubilantbiosys.com](mailto:kailash_swarna@jubilantbiosys.com)

### ***For Media***

Seema Ahuja

VP-Corporate Marketing & Communications

Jubilant Organosys Ltd

+919810631779,

[seema\\_ahuja@jubl.com](mailto:seema_ahuja@jubl.com)

### **Disclaimer:**

Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Organosys may, from time to time, make additional written and oral forward looking statements, including statements contained in the Company's filings with the regulatory bodies and its reports to shareholders. The Company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.